卡格列净联合利拉鲁肽对2型糖尿病患者体重有额外降低效应,但对HbA1c无额外效应
45例二甲双胍(伴或不伴磺脲类)治疗控制不佳的2型糖尿病患者随机接受利拉鲁肽1.2mg/日、卡格列净100mg/日或两者联合治疗16周。联合治疗HbA1c降幅未优于单药,但体重降幅大于各单药;卡格列净单药使基础内源性葡萄糖生成率(EGP)增加9%,联合治疗使EGP增加15%,利拉鲁肽未能阻断卡格列净引起的EGP增加。
要点
- 联合治疗体重降幅-6.0±0.8 kg,大于卡格列净单药-3.5±0.5 kg和利拉鲁肽单药-1.9±0.8 kg。
- 卡格列净单药使基础EGP率增加9%(P<0.05),联合治疗使EGP增加15%(P<0.05)。
- 利拉鲁肽未能阻断卡格列净引起的EGP增加,这解释了联合治疗对HbA1c无额外效应。
核心结论
- 利拉鲁肽未能阻断卡格列净引起的内源性葡萄糖生成(EGP)增加,尽管阻断了卡格列净引起的血浆胰高血糖素升高并防止了血浆胰岛素浓度下降。
- 利拉鲁肽未能阻止卡格列净引起的EGP增加,这解释了两种药物对HbA1c缺乏额外效应。
研究设计与样本
- 45例二甲双胍(伴或不伴磺脲类)治疗控制不佳(HbA1c 7-11%)的2型糖尿病患者,接受9小时[3-3H]葡萄糖输注EGP测量后随机分组。
- 随机接受利拉鲁肽1.2 mg/日(LIRA)、卡格列净100 mg/日(CANA)或利拉鲁肽1.2 mg联合卡格列净100 mg(CANA/LIRA)治疗16周,16周时重复EGP测量。
主要发现
- HbA1c自基线至16周平均降幅:CANA/LIRA组-1.67±0.29%(P=0.0001),CANA组-0.89±0.24%(P=0.002),LIRA组-1.44±0.39%(P=0.004)。
- 体重降幅:CANA/LIRA组-6.0±0.8 kg(P<0.0001),CANA组-3.5±0.5 kg(P<0.0001),LIRA组-1.9±0.8 kg(P=0.03)。
- CANA单药使基础EGP率增加9%(P<0.05),伴血浆胰高血糖素与胰岛素比值增加50%(P<0.05)。
- LIRA单药降低血浆胰高血糖素浓度并抑制EGP。
- CANA/LIRA组EGP增加15%(P<0.05),尽管血浆胰岛素反应维持在基线水平且卡格列净引起的血浆胰高血糖素升高被阻断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the effect of combination therapy with canagliflozin plus liraglutide on HbA1c, endogenous glucose production (EGP), and body weight versus each therapy alone. RESEARCH DESIGN AND METHODS: Forty-five patients with poorly controlled (HbA1c 7-11%) type 2 diabetes mellitus (T2DM) on metformin with or without sulfonylurea received a 9-h measurement of EGP with [3-3H]glucose infusion, after which they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks. At 16 weeks, the EGP measurement was repeated. RESULTS: The mean decrease from baseline to 16 weeks in HbA1c was -1.67 ± 0.29% (P = 0.0001), -0.89 ± 0.24% (P = 0.002), and -1.44 ± 0.39% (P = 0.004) in patients receiving CANA/LIRA, CANA, and LIRA, respectively. The decrease in body weight was -6.0 ± 0.8 kg (P < 0.0001), -3.5 ± 0.5 kg (P < 0.0001), and -1.9 ± 0.8 kg (P = 0.03), respectively. CANA monotherapy caused a 9% increase in basal rate of EGP (P < 0.05), which was accompanied by a 50% increase (P < 0.05) in plasma glucagon-to-insulin ratio. LIRA monotherapy reduced plasma glucagon concentration and inhibited EGP. In CANA/LIRA-treated patients, EGP increased by 15% (P < 0.05), even though the plasma insulin response was maintained at baseline and the CANA-induced rise in plasma glucagon concentration was blocked. CONCLUSIONS: These results demonstrate that liraglutide failed to block the increase in EGP caused by canagliflozin despite blocking the rise in plasma glucagon and preventing the decrease in plasma insulin concentration caused by canagliflozin. The failure of liraglutide to prevent the increase in EGP caused by canagliflozin explains the lack of additive effect of these two agents on HbA1c.
引用
- Ali AM, Martinez R, Al-Jobori H, et al. Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes. Diabetes Care. 2020. PMID: 32220916. doi:10.2337/dc18-2460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。